Qpex Biopharma

We’re an AMR-focused infectious disease company. Our team has a rich history of innovation in antibiotic development. Now a Shionogi Group company

[Qpex Biopharma @Qpexbio]

Xeruborbactam (formerly QPX7728) is a highly differentiated ultra-broad-spectrum beta-lactamase inhibitor in clinical studies in IV & oral forms for #AMR. Hear from one of the inventors, our head of chemistry @Scottjhecker on how to pronounce the new given name “xeruborbactam”:

[Qpex Biopharma @Qpexbio]

Antimicrobial resistance (AMR) occurs when pathogens develop resistance to the medicines designed to treat them. It's a growing global health threat. In this @Nature supplement, Gareth Morgan explores economic solutions to drive antibiotic innovation. https://t.co/0n1mYIaZAU

[Qpex Biopharma @Qpexbio]

Great news for national preparedness and advancing solutions for #AMR. Congrats to the @ShionogiUS team!

[Shionogi Inc. (U.S.) @ShionogiUS]

#News: @BARDA has awarded Shionogi Inc. a new contract to advance our #antibiotic against biothreats and drug-resistant pathogens. Initially funded at $119M with options up to $482M, this contract also supports a new U.S. manufacturing site and procurement.
https://t.co/zAviirAoCi

[Qpex Biopharma @Qpexbio]

#NEWS: We welcome Gareth Morgan, longstanding Shionogi team member and global leader, to Qpex as President.

Morgan succeeds @MikeMndudley , Pharm.D., who is retiring and will serve as a strategic advisor to Qpex and Shionogi.

Learn more: https://t.co/vANlqvMatH

[Qpex Biopharma @Qpexbio]

We look forward to continuing collaboration with leaders like Dr. Jacinda Abdul-Mutakabbir, AKA Dr. JAM at our new San Diego, R&D facility.

A researcher, educator and clinician, she sees resistant infection problems from multiple POVs.

Learn more: https://t.co/GulmrO91zZ

[Qpex Biopharma @Qpexbio]

We were honored to have Dr. Karen Bush share her perspectives at the opening of our new antimicrobial R&D facility in San Diego. Throughout her career, Dr. Bush has driven innovation through industry, government and academic collaborations.

Learn more: https://t.co/tFjWHBIBme

[Qpex Biopharma @Qpexbio]

We recently celebrated the official opening of our expanded U.S.-based drug discovery lab in San Diego, which will support antimicrobial research and development (R&D) for decades to come.

Learn more: https://t.co/GulmrO91zZ

[Qpex Biopharma @Qpexbio]

Welcome Lynn Connolly, MD, PhD as Chief Medical Officer. With more than 12 years of experience in developing infectious disease treatments, she will lead our clinical development programs and help drive innovation in our expanding drug discovery programs.

[Qpex Biopharma @Qpexbio]

@Qpexbio is committed to continuing its position as a leader in innovation and development of therapies in infectious diseases. We are honored to have Michael Dudley presenting at @SIDPharm annual meeting held in conjunction with @IDWeekmtg .

[Shionogi Inc. (U.S.) @ShionogiUS]

At the @SIDPharm Annual Meeting, Michael Dudley, PharmD, President & CEO of @Qpexbio, a Shionogi Group Company, will deliver the keynote address. He’ll share insights from his journey in academia to industry R&D, highlighting his role in developing four key antibiotics. #SIDP2024

[Qpex Biopharma @Qpexbio]

Important discussion ahead of UN meetings.

[CMI Communications @CMIComms]

Our next #Communicable episode on pipeline #antibiotics is dropping Monday. Swipe for a preview of what’s in store for you!

@ErinMcCreary @MikeMndudley @Qpexbio @EMA_News @ESCMID
#IDtwitter #IDxposts #CMIComunications #OpenAccess

[Biocom @Biocom]

In July's LifeLines Newsletter, discover how Yatiri Bio uses proteomics to revolutionize cancer drug discovery, how the Shionogi lab @Qpexbio progresses antimicrobial resistance research, and how our members drive precision medicine forward. Read more: https://t.co/Psos4NQXDz

[Qpex Biopharma @Qpexbio]

“The expertise of @ShionogiUS & @Qpexbio scientists in this facility in the U.S. will enhance drug discovery and development efforts & help make medicines available that can support future public health,economic & nat’l security concerns.”- Phyllis Arthur, Exec VP @IAmBiotech

[Shionogi Inc. (U.S.) @ShionogiUS]

#ICYMI: We’re establishing our first discovery laboratory in the U.S. The R&D facility for @Qpexbio, a Shionogi Group Company, will build on our longstanding legacy in infectious disease. Learn more: https://t.co/l0SpZNXVeB

#BIO2024

[Qpex Biopharma @Qpexbio]

@Qpexbio scientists will present microbiological data and Phase 1 results for oral xeruborbactam - the first orally bioavailable beta-lactamase inhibitor with inhibitory activity against both serine and metallo beta-lactamases.

[Shionogi Inc. (U.S.) @ShionogiUS]

Pathogens will always stay one step ahead of available treatments and that’s why we're committed to developing new antibiotics. Together with @Qpexbio, we're presenting new data on our investigational beta-lactamase inhibitor at #ESCMIDGlobal. ​

Learn more about our pipeline at https://t.co/SEtUXQgM1K​

#ECCMID2024

[Qpex Biopharma @Qpexbio]

Our CEO @MikeMndudley joined a roundtable of experts to discuss the importance of changes in policy and where he emphasized the importance of application of new improved methods to show value of antibiotics. @NPLB_org @CARB_X @SIDPharm @gardp_amr @IDSAInfo @AWG_News @ShionogiUS

[SIDP @SIDPharm]

🆕 #Breakpoints Episode:

Join @hboucher3, Ramy Elshaboury, @MikeMNDudley & @MeganKlatt3 to discuss barriers to abx drug development, incentives & legislation to promote market growth, & what we can do to ensure the abx pipeline doesn’t run dry.

🎧 https://t.co/ez0n3ae0fR

[Shionogi Inc. (U.S.) @ShionogiUS]

Time is of the essence for patients with infections caused by carbapenem-resistant pathogens. Mortality risk increases with every hour that treatment is delayed.

Learn more about Gram-negative bacterial resistance and treatment strategies with @GoHealio: https://t.co/sxwR1cPpMw

[Qpex Biopharma @Qpexbio]

Qpex is now a Shionogi Group Company. Read what that means about @ShionogiUS commitment to infectious dieases and #AMR https://t.co/igplYmcvrr

[Qpex Biopharma @Qpexbio]

Oral and IV xeruborbactam combinations. It’s early! Thursday 10/12 at 8am ET Room 104.

[Shionogi Inc. (U.S.) @ShionogiUS]

Attending #IDWeek2023? Join Olga Lomovskaya, PhD, SVP, Discovery and Clinical Microbiology, @Qpexbio, on October 12 to hear about new antimicrobials in the pipeline. #InfectiousDiseases

[Qpex Biopharma @Qpexbio]

Data on xeruborbactam combinations presented at last year’s @IDWeekmtg 2022 are now published. @CARB_X @AMRActionFund @SIDPharm @ShionogiUS @IDSAInfo @pewhealth @AWG_News @ABsteward @CDC_AR @saveantibiotics @gardp_amr @AntibioticsThe #AMR

[Mike Dudley @MikeMndudley]

Beta-lactamase inhibitors have been an important strategy for combatting #AMR. Want to finally see comparative head-to-head data on investigational & marketed beta-lactamase inhibitors? We publish results here… https://t.co/V5Y5UlqAXI

[Qpex Biopharma @Qpexbio]

Important milestone in this unique and important collaboration. @SIDPharm @IDSAInfo @AWG_News @CARB_X @AMRActionFund @pewhealth @ABsteward @TimothyJinks1 @victornizet

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

We’re delighted to announce that we’ve signed an agreement with Orchid Pharma Ltd to manufacture cefiderocol 👏

This agreement is a critical step forward in our project with @SHIONOGI_JP  & @CHAI_health to improve appropriate antibiotic access

👉https://t.co/H8Ce1AArQH

[Qpex Biopharma @Qpexbio]

@SIDPharm @IDSAInfo @AWG_News @CDC_AR @AMRActionFund @CARB_X #AMR @ABsteward @pewhealth @gardp_amr @AMRCongress @GlobalAMRHub @MAD_ID_ASP @ASMicrobiology #IDWeek2023

[Mike Dudley @MikeMndudley]

#AMR due to NDM beta-lactamase continues to amaze in its evolution, including NDM-9 & resistance to some beta-lactamase inhibitors. We describe here: https://t.co/VrJ2ApHFFI

[Qpex Biopharma @Qpexbio]

Qpex and Shionogi announce presentations at #IDWeek2023
https://t.co/Cu9RbjHsoI